galm pharmaceut ltd glmd buy pt aramchol work nash favor risk/reward
upgrad buy hold price analyst jason mccarthi ph full summari
inc buy pt soft end solid tax cut proce boost
immutep limit immp buy pt rais capit extend runway expand new combin
studi keytruda analyst jason mccarthi ph full summari
 buy pt focu infecti diseas pipelin near-term hepb zika
corpor event call maxim salesperson inform
cover ndr boston cfo golder wed jun
nic inc cover kinstling ndr nyc cfo steve kovzan vice-president corpor commun
corpor ctrl cover chokshi ndr boston ny cfo mark novakovich mon tue may
profir energi inc pfie host jang ndr nyc ceo brendan hatch cfo ryan oviatt wed thur
aramchol work nash favor risk/
reward upgrad buy hold price
galm report spend close period
cash burn rate galm runway
next inflect point data arrest studi aramchol
nash expect
upgrad share buy hold galm valuat pull back follow
data arriv studi announc februari aramchol vs placebo
hiv-associ fatti liver diseas prompt us lower rate
hold howev base review arriv publish literatur well
manag discuss earn confer call tuesday morn
march believ signific differ arriv
arrest must consid differ includ indic
diseas patholog hiv fatti liver diseas vs nash trial size vs
time week vs week well factor
cross studi comparison predict good bad outcom arrest
difficult imposs focu view remain
design arrest nash base posit valu data prior
studi nash trial size endpoint believ current
valuat point favor risk/reward profil lead us upgrad
share buy
hasten add arrest still binari event risk avers investor
may want wait data view may consid aggress
see arriv studi result reliabl predictor outcom
arrest consid arrest base factor
believ risk/reward favor see soon data expect
next signific event compani
set price target model approv discount back use
rate discounted-ep sum-of-the-part model
equal weight averag deriv price target
recal arrest studi global multi-cent random doubl blind
placebo-control trial evalu treatment effect safeti aramchol
patient biopsi proven nash overweight obes
pre-diabet type-ii diabet arrest studi durat week
follow-up period result anticip announc
primari endpoint previous demonstr phase iia studi reduct liver
fat content measur magnet reson spectroscopi mr secondari
histolog endpoint includ improv fibrosi two-point improv
nafld activ score na resolut nash arrest studi also
arriv trial meet primari endpoint howev studi
investigator-sponsor evalu potenti aramchol new indic
hiv-associ fatti liver diseas diseas signific differ nash
molecular level arriv random double-blind placebo-
control studi treat patient week goal establish proof-
of-concept poc aramchol versu placebo patient
primari endpoint studi improv liver fat week measur
mri-pdff liver biopsi includ part evalu pilot
trial unfortun trial show signific differ though drug
safe well toler
click full note
focu infecti diseas pipelin near-term
inovio report revenu mileston grant net loss
compani end period cash inovio receiv
up-front payment apollobio neeq develop
commerci greater china china hong kong macao
taiwan potenti korea combin inovio cash runway
addit non-dilut sourc capit grant partnership could
extend runway
phase program reveal studi on-going expect
report data key event compani addit immun
oncolog pipelin includ sever studi head neck cervic
bladder brain cancer on-going compani plan expand
studi anal dysplasia data studi could start emerg
late
expect infecti diseas pipelin could provid increment
catalyst stock data report inovio announc posit
data hepb vaccin demonstr hepb-specif immun
respons across dose cohort addit data expect
also expect data updat and/or public vaccin includ
mer zika hiv well dna-bas monoclon antibodi dmab
inovio intend leverag infecti diseas pipelin gener
conclus expect multipl infecti diseas program
continu advanc report data provid increment catalyst
stock non-dilut fund wait data immune-
oncolog pipelin data
pivot studi program includ two studi reveal
reveal patient cin cervic intraepitheli neoplasia
associ hpv type across studi center global manufactur
scale commerci cellectra electropor devic
readi go reveal studi random two one double-blind
placebo-control remind target protein hpv
viru patient studi receiv intramuscular electropor
cellectra day placebo cellectra primari endpoint
studi percent patient evid cervic high grade squamou
intraepitheli lesion histolog evid and/or
week phase ii studi treatment result histopatholog
regress diseas meet studi primari endpoint
addit trial demonstr clearanc hpv conjunct regress
pipelin addit on-going pivot program studi underway
hpv-relat high grade vulvar lesion combin studi
checkpoint plu dna base glioblastoma bladder cancer
underway trial open-label posit data far prostat
cancer recal roch return asset inovio inovio complet
trial monotherapi believ next step combin trial
checkpoint expect updat across infecti diseas pipelin includ
unnam ebola zika vaccin first human studi zika conduct
click full note
rais capit extend runway
expand new combin studi keytruda
immutep recent announc capit rais institut investor
bring issuanc ordinari share
price per ordinari share per estim immutep
current cash balanc sheet burn rate
per quarter provid runway
concurr capit rais immutep announc collabor
suppli agreement merck nr evalu immutep solubl
eftilagimod efti combin keytruda treat
solid tumor lung head neck ovarian trial studi
patient expect initi
second combin studi keytruda recal studi melanoma
on-going data updat expect
addit combin studi keytruda also expect see
data updat on-going studi chemotherapi breast
cancer well updat time disclos progress
partner novarti solid tumor glaxosmithklin
conclus view capit rais posit immutep small
discount warrant extend runway posit compani
reach next set catalyst includ second
combin studi keytruda continu believ could
next checkpoint emerg pair
immutep lead candid develop immun
adjuv immun stimul solubl dimer recombin form
fusion protein use increas immun respons tumor
stimul dendrit cell high affin bind mhc class ii molecul
dendrit cell surfac one two protein shown abl properli
condit dendrit cell monocyt undergo matur step
stimul antigen target t-cell ligand what import
note without inflamm
develop dr frdric triebel late dendritic-cel activ
use low dose use t-cell adjuv cancer vaccin
higher dose combin cancer chemotherapi ramp
immun respons drive dendrit cell monocyt increas tumor antigen
larg indic right partner novarti nv nr licens
develop combin therapi inhibitor solid tumor
on-going clinic studi multipl cancer type januari expand
enrol anoth patient novarti also initi anoth
program hematolog solid cancer combin inhibitor
glaxosmithklin gsk nr evalu phase studi
psoriasi trial expect complet march immutep receiv
single-digit royalti partnership lead in-hous program
antigen-pres cell apc activ ramp t-cell product follow
chemotherapi alreadi demonstr poc breast cancer current
phase iib registr studi could launch phase studi
combin keytruda melanoma patient also posit far
demonstr tumor reduct patient collabor merck
phase ii trial multipl solid tumor expect commenc
click full note
soft end solid tax cut proce
maintain buy rate price target del follow
releas decemb result
pro forma ep estim
street mean howev revenu comp line consensu
far march comp run pace expect
compani barbel menu strategi contribut full-year comp
high end guidanc
lower ep estim expect
reinvest tax cut proce support comprehens brand refresh
nevertheless above-consensu ep estim vs
guidanc consensu reflect strong top-lin growth benign food
cost slight moder labor cost next quarter
still regard growth reason price stori thu view
valuat attract
ep pro forma actual vs maxim street
revenu actual vs maxim street
comp actual vs maxim street
restaurant-level ebitda margin actual vs maxim
street
oper margin pro forma actual vs maxim street
pro forma
ep initi guidanc vs maxim street pre-releas
revis estim
comp initi guidanc posit vs maxim pre-
releas estim unchang
revenu initi guidanc vs maxim
street pre-releas revis estim
restaurant-level ebitda margin initi guidanc vs
maxim street pre-releas revis estim
net new unit growth unit vs unit maxim pre-releas street
project net new unit growth unit
tax rate vs maxim estim pre-reform baselin
revis baselin
attract valuat use base valuat year three differ
valuat methodolog equal weight forward price-to-earnings multipl base
multipl yield price target forward ev/ebitda multipl
base multipl yield price target forward sale multipl
base multipl yield price target methodolog arriv
price target round
click full note
maintain buy rate price target chipotl mexican
grill follow news compani chief market offic mark
crumpack exit compani effect today
regard today news sign new ceo brian niccol move quickli
take action make presenc known
cmg chief market offic mark crumpack exit compani effect
today mr crumpack serv compani sinc mr crumpack
led effort restor compani imag sever food safeti scare late
recent guid compani digit off-premis effort
term separ agreement mutual agre upon mr
crumpack manag detail morn releas
mr crumpack forgo retent bonu receiv
januari though entitl six month sever pay
regard today news sign new ceo brian niccol move quickli
take action make presenc known view mr niccol assum
ceo posit march check box regard brand
leadership menu innov technolog intern franchis develop
experi surpris see turnov execut suit mr niccol
arriv expect addit departur next month moreov
would surpris see former alumni
nr mr niccol serv bell ceo sinc varieti
brand leadership posit sinc join mr niccol also rule
potenti newly-cr executive-level posit notabl
still argu pullback share provid opportun investor
particip compani recoveri anticip return robust
strong sale earn growth next quarter believ retreat
commod cost restaurant-level effici gain reinforc margin
expans buyback provid increment ep upsid ep
estim unchang vs consensu
vs consensu reflect forecast mid-single-digit comp
growth benign food cost acceler margin leverag increas digit
multipli forward price-to-earnings target unchang ep estim
arriv price target round correspond
forward ev/ebitda ratio long-run averag
garner prior coli outbreak cmg short float percentag
total float weight industri averag
better-than-expect result updat guidanc potenti trigger short-
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
